Novo Nordisk A/S Stock News

Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.

Novo Nordisk is a leader and innovator in the diabetes drug market. The pharmaceutical company is making strides in obesity care, too.

Novo Nordisk recently presented encouraging phase 1 results for an oral obesity treatment candidate. The company has many more promising programs in its early-stage pipeline.

Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.

Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.

By definition, mega-cap stocks are those which possess a market capitalization above $200 billion. So, investors seeking to turn $10,000 into $1 million through Mega cap companies will be choosing fro

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novo Nordisk primarily focuses on the diabetes and obesity markets with medications like Ozempic and Wegovy. Wegovy was recently granted an extended indication from the FDA to treat cardiovascular dis

When many investors hear the word mania, they may think of artificial intelligence (AI) stocks or Bitcoin. Both investments have yielded market-beating returns and have room to run higher.

Pfizer's pipeline already includes two obesity drugs. However, doubts about Pfizer's lead obesity program could make buying Viking a smart move.

Novo Nordisk's $600 billion valuation makes it one of the top healthcare companies in the world. For investors looking for stocks with more upside, upstart Zealand Pharma may fit the bill.

We're bullish on the market this year, notes Andrew Arons. He discusses the long-term market outlook.

Who is better, the United States of America or the European Union? On the one hand, European citizens are by and large privy to free access to healthcare, though the land of the free is considerably l

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Seq

A research firm added the European pharmaceutical sector star to its focus list. It was among four stocks earning this status.